SEC Company Response from Hepion Pharmaceuticals, Inc. (HEPA, CTRVP) (CIK 0001583771) (HEPA) — Apr 22, 2019
Hepion Pharmaceuticals, Inc. (HEPA, CTRVP) (CIK 0001583771)
Date: April 22, 2019 · CIK: 0001583771 · Accession: 0001104659-19-022894
AI Filing Summary & Sentiment
File numbers found in text: 333-229416
Letter
Re: ContraVir Pharmaceuticals, Inc.
April 22, 2019
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, DC 20549
Attention: Todd Schiffman
Registration Statement on Form S-1, as amended
File No. 333-229416
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), ContraVir Pharmaceuticals, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5:00 p.m. (EDT) on Wednesday April 24, 2019, or as soon thereafter as possible.
Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at 212-634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
Thank you,
CONTRAVIR PHARMACEUTICALS, INC.
By:
/s/ Robert Foster
Name:
Robert Foster
Title:
Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm April 22, 2019 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, DC 20549 Attention: Todd Schiffman Re: ContraVir Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended File No. 333-229416 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), ContraVir Pharmaceuticals, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5:00 p.m. (EDT) on Wednesday April 24, 2019, or as soon thereafter as possible. Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at 212-634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request. Thank you, CONTRAVIR PHARMACEUTICALS, INC. By: /s/ Robert Foster Name: Robert Foster Title: Chief Executive Officer 1